Literature DB >> 26597718

Intravenous iron administration in restless legs syndrome : An observational study in geriatric patients.

Benjamin Lieske1, Ingrid Becker2, Ralf Joachim Schulz1, Maria Cristina Polidori3, Jan Kassubek3, Gabriele Roehrig4,5.   

Abstract

BACKGROUND: This observational study was carried out to investigate the effect of intravenous (i.v.) iron administration on the clinical symptoms of restless legs syndrome (RLS) in geriatric outpatients over 65 years old.
METHODS: In this study geriatric outpatients (mean 4.5 ± 3.4 comorbidities and 5.7 ± 4.4 drugs taken) were recruited according to the following inclusion criteria: ≥ 65 years, diagnosis of RLS due to iron deficiency, i.e. ferritin < 50 µg/l or transferrin saturation (TFS) < 16 %) as well as no other iron therapy within 2 weeks prior to the study. Of the patients 7 (41 %) received 500 mg ferric carboxymaltose (FCM) and 10 patients (59 %) received iron gluconate (62.5 mg) based on the degree of iron deficiency. As assessed by the international RLS severity scale (IRLS) symptoms were recorded 3 times: at the beginning of iron therapy (t0), after 2 weeks (t1) and after 12 weeks (t2).
RESULTS: A total of 17 patients (13 female, 4 male, mean age 73.2 ± 5.9 years) were included. The IRLS score significantly improved in all patients as shown by an average decrease from 30.2 (± 4.3) to 20.2 (± 4.7) (p < 0.001) after 2 weeks of i.v. iron treatment and to 23.2 ± 6.6 (p < 0.001) after 12 weeks. There was a high correlation between ferritin values and the IRLS score (C 0.729, p < 0.001). The part of the IRLS referring to activities of daily living (ADL) improved from a median of 3 (scores 3-4) to 2 (scores 2-3, p = 0.001) after 2 weeks (effect size - 0.6).
CONCLUSION: In this study group of geriatric outpatients i.v. administration of iron was associated with a significant improvement of symptoms in RLS as assessed by the IRLS score 2 weeks after treatment. In geriatric patients with RLS associated with iron deficiency, i.v. iron administration should be considered regarding improvement of RLS symptoms and ADL.

Entities:  

Keywords:  Activities of daily living; Aged; Geriatrics; Iron deficiency; Severity scale

Mesh:

Substances:

Year:  2015        PMID: 26597718     DOI: 10.1007/s00391-015-0984-y

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  22 in total

Review 1.  Iron for restless legs syndrome.

Authors:  Lynn M Trotti; Srinivas Bhadriraju; Lorne A Becker
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.

Authors:  Richard P Allen; William G Ondo; Eric Ball; Michael O Calloway; Ranjani Manjunath; Rachel L Higbie; Mechele R Lee; Paul A Nisbet
Journal:  Sleep Med       Date:  2011-04-13       Impact factor: 3.492

3.  Prevalence and characteristics of restless legs syndrome (RLS) in the elderly and the relation of serum ferritin levels with disease severity: hospital-based study from Istanbul, Turkey.

Authors:  Asli Çurgunlu; Alper Döventaş; Derya Karadeniz; Deniz Suna Erdinçler; Ayşe Kutlu Oztürk; Yesari Karter; Adnan Yaldiran; Fikret Sipahioğlu; Tanju Beğer
Journal:  Arch Gerontol Geriatr       Date:  2011-06-30       Impact factor: 3.250

4.  A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome.

Authors:  B J Davis; A Rajput; M L Rajput; E A Aul; G R Eichhorn
Journal:  Eur Neurol       Date:  2000       Impact factor: 1.710

Review 5.  Insight into the pathophysiology of restless legs syndrome.

Authors:  C J Earley; R P Allen; J L Beard; J R Connor
Journal:  J Neurosci Res       Date:  2000-12-01       Impact factor: 4.164

6.  Investigating the response to intravenous iron in restless legs syndrome: an observational study.

Authors:  Magdolna Hornyak; Hanna Scholz; Andrea Kiemen; Jan Kassubek
Journal:  Sleep Med       Date:  2012-04-12       Impact factor: 3.492

7.  Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.

Authors:  Richard P Allen; Charles H Adler; Wei Du; Angelia Butcher; David B Bregman; Christopher J Earley
Journal:  Sleep Med       Date:  2011-10-05       Impact factor: 3.492

8.  A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome.

Authors:  Ludger Grote; Lena Leissner; Jan Hedner; Jan Ulfberg
Journal:  Mov Disord       Date:  2009-07-30       Impact factor: 10.338

9.  Prevalence and clinical correlates of restless legs syndrome in an elderly French population: the synapse study.

Authors:  Sébatien Celle; Frédéric Roche; Judith Kerleroux; Catherine Thomas-Anterion; Bernard Laurent; Isabelle Rouch; Vincent Pichot; Jean Claude Barthélémy; Emilia Sforza
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-11-13       Impact factor: 6.053

10.  Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population.

Authors:  R A Hamilton; L L Briceland; M H Andritz
Journal:  Pharmacotherapy       Date:  1998 Sep-Oct       Impact factor: 4.705

View more
  3 in total

1.  [Anemia in the aged].

Authors:  Gabriele Röhrig
Journal:  Z Gerontol Geriatr       Date:  2018-11-29       Impact factor: 1.281

2.  Efficacy of Intravenous Iron Sucrose in Hemodialysis Patients with Restless Legs Syndrome (RLS): A Randomized, Placebo-Controlled Study.

Authors:  Yinghui Deng; Jinglin Wu; Qiang Jia
Journal:  Med Sci Monit       Date:  2017-03-12

3.  Does Repeated Dosing of Intravenous Ferric Carboxymaltose Alleviate Symptoms of Restless Legs Syndrome?

Authors:  Hea Ree Park; Su Jung Choi; Eun Yeon Joo
Journal:  J Clin Med       Date:  2022-03-17       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.